XML 40 R30.htm IDEA: XBRL DOCUMENT v3.26.1
Sale of PerClot (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Jul. 28, 2021
Jan. 31, 2026
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Total revenues     $ 116,337 $ 98,978  
Per Clot          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Consideration for sale of assets $ 41,000       $ 5,000
Total revenues     600 $ 800  
Gain from sale of non-financial assets         7,000
Notes and loans receivable     5,000   5,000
Per Clot | Transfer Of Perclot Manufacturing Equipment          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Contingent consideration receivable 800        
Per Clot | Starch Medical Inc.          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Contingent liability payment 4,500 $ 1,500      
Payable     $ 1,500   $ 3,000
Per Clot | Upon Our Receipt of Premarket Approval          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Proceeds from sale of assets 18,800        
Per Clot | Artivion Inc. And Starch Medical Inc.          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Consideration for sale of assets 54,500        
Proceeds from sale of assets 25,000        
Per Clot | Artivion Inc. And Starch Medical Inc. | Baxter Achievement Of Worldwide Sales          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Contingent consideration receivable 10,000        
Per Clot | Starch Medical Inc.          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Consideration for sale of assets 13,500        
Contingent liability payment 6,000        
Per Clot | Starch Medical Inc. | Baxter Achievement Of Worldwide Sales          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Contingent liability payment $ 3,000